apolipoprotein E4

Overview

Apolipoprotein E4 (APOE4) is a protein isoform encoded by the APOE gene, located on chromosome 19, and represents one of three common isoforms of apolipoprotein E (APOE2, APOE3, and APOE4) distinguished by single amino acid substitutions at positions 112 and 158. As the major cholesterol carrier in the central nervous system (CNS), APOE plays a fundamental role in lipid transport, cholesterol homeostasis, and synaptic maintenance across neural tissues. The APOE4 isoform is distinguished from the more common APOE3 variant by the substitution of arginine for cysteine at position 112, a structural change that profoundly alters the protein's receptor-binding properties, lipid affinity, and metabolic behavior. APOE is also expressed in peripheral tissues, including the liver, and participates in systemic lipid metabolism, immune regulation, and vascular biology.

The APOE4 allele is the most significant known genetic risk factor for late-onset Alzheimer's disease (AD), with each inherited copy conferring approximately a two- to three-fold increased risk relative to the neutral APOE3 background. Homozygous APOE4 carriers face up to a 10- to 15-fold elevated risk compared to APOE3 carriers. Beyond Alzheimer's disease, APOE4 has been implicated in a broad spectrum of conditions including cardiovascular disease, neuroinflammation, and age-related ocular degeneration, positioning it as a high-priority therapeutic and biomarker target across multiple disease domains.

Focus of Latest Publications

Recent publications on apolipoprotein E4 (APOE4) have focused primarily on its role in Alzheimer’s disease and on broader cholesterol- and lipid-related biology. In a proteome-wide association study of Alzheimer’s disease, APOE was identified as a candidate gene in the African American analysis, supporting a putative causal relationship through cis regulation of plasma protein abundance. In a separate study of cognitively normal midlife postmenopausal women, APOE4-related differences in memory-based functional neuroimaging outcomes were examined to probe early brain vulnerability in verbal memory systems, reflecting interest in how APOE4 may shape preclinical cognitive and neuroimaging phenotypes.

Several recent papers also linked APOE/APOE4 to cholesterol transport, redox balance, and metabolic reprogramming. A cerebrospinal fluid biomarker study measured reduced, reversibly oxidized, and irreversibly oxidized apoE and found that apoE3/E4 carriers had higher irreversibly oxidized apoE, consistent with reduced buffering capacity. The same work showed that maintaining the reduced monomeric state was associated with improved cholesterol transport efficiency, while shifts toward oxidation reflected altered CNS pathophysiology. Outside the CNS, APOE appeared in multi-omics studies of tumor and metabolic biology: in colorectal cancer, an SPP1+ APOE+ tumor-associated macrophage subset was linked to CYP27A1-mediated 26-hydroxycholesterol metabolism, immunosuppression, and reduced CD8+ T-cell infiltration; in prostate cancer, APOE was identified among key lipid metabolism regulators associated with fatty acid and cholesterol pathways; in thyroid cancer, APOE was included in a 3-gene prognostic model with PRR15 and C3; and in a nanoplastics toxicity study, APOE was among regulators implicated in oxidative stress and disrupted lipid metabolism.

Therapeutic and translational publications emphasized APOE4 as a target for gene editing and precision medicine. A review on CRISPR-based correction of APOE4 described nuclease disruption, base editing, and prime editing as strategies to modify the allele at its genomic source, with particular attention to delivery systems such as nanoparticles and extracellular exosomes. The review highlighted recent exosome-mediated APOE4 editing advances while noting major barriers, especially blood–brain barrier delivery, allele specificity, and long-term genomic safety. Another review discussed gene editing technologies as a way to enhance stem cell therapy for Alzheimer’s disease by targeting APOE4 and other risk factors, aiming to improve disease modeling, neuroinflammation control, and neuroprotection. In dyslipidemia research, APOE polymorphisms were also examined for their impact on statin efficacy and safety, underscoring continued interest in APOE-related variation in lipid-lowering treatment response.